| Literature DB >> 16296807 |
Marco van de Weert1, Lene Jorgensen, Eva Horn Moeller, Sven Frokjaer.
Abstract
Protein pharmaceuticals have matured into an important class of drugs, now comprising one in three novel drugs introduced on the market. However, significant gains are still to be made in reducing the costs of production, ensuring proper pharmacokinetics and efficacy, increasing patient compliance and convenience, and reducing side effects such as immunogenicity. This review summarises these issues and provides recent examples of methods to reduce costs, alter pharmacokinetics and increase patient compliance. It also discusses the increasing interest in understanding immunogenicity in order to prevent failure of the protein drug or serious life-threatening side effects due to autoimmunogenicity.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16296807 DOI: 10.1517/17425247.2.6.1029
Source DB: PubMed Journal: Expert Opin Drug Deliv ISSN: 1742-5247 Impact factor: 6.648